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Abstract 
Background: Severe falciparum malaria may be complicated by haemolysis after parasite clearance, however the 
mechanisms remain unclear. Recent reports describe a pattern of delayed onset haemolysis among non-immune 
travellers with hyperparasitaemia treated with intravenous artesunate, termed post-artesunate delayed haemolysis 
(PADH). The occurrence and clinical impact of PADH following severe malaria infections in areas of unstable transmis-
sion are unknown.
Case: A 45-year-old Bangladeshi male was initially admitted to a local hospital with severe falciparum malaria compli-
cated by hyperparasitaemia and treated with intravenous artesunate. Twenty days from his first presentation he was 
readmitted with delayed onset haemolytic anaemia and acute kidney injury. Multiple blood transfusions and haemo-
dialysis were required. Renal biopsy revealed acute tubular injury and haem pigment nephropathy. His haemoglobin 
and renal function recovered to baseline after 62 days from his second admission.
Discussion: This case highlights the differential diagnosis of post-malaria delayed onset haemolysis, including the 
recently described syndrome of post-artemisinin delayed haemolysis. The pathophysiology contributing to acute 
kidney injury in this patient and the limited treatment options are discussed.
Conclusions: This report describes PADH complicated by acute kidney injury in an adult patient living in a malaria 
hypoendemic region who subsequently required blood transfusions and haemodialysis. This case emphasizes the 
importance of routine follow up of haemoglobin and renal function in artesunate-treated patients who have recov-
ered from severe malaria.
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Background
Delayed onset haemolytic anaemia is a recognized but 
infrequent complication during recovery after severe 
falciparum malaria infection. The course of anaemia fol-
lowing severe malaria is often protracted and, in those 
treated with quinine, haemoglobin may not return 
to baseline until 28  days after infection [1]. Prior to 
the introduction of artesunate, prolonged haemolysis 
contributed to this delayed haemoglobin recovery in less 
than 7% of patients [1]. The mechanisms of continued 
haemolysis after parasite clearance are unclear, with both 
auto-immune and non-immune processes implicated in 
the absence of artesunate treatment [2–4]. Recent reports 
describe a syndrome termed post-artemisinin delayed 
haemolysis (PADH) following treatment with intrave-
nous artesunate [5–11]. PADH usually occurs 1–3 weeks 
after artesunate is administered to non-immune travel-
lers with high parasitaemia. The different patterns of 
haemolysis following malaria infection and artesunate 
treatment highlight the complexity of malaria anaemia.
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Massive haemolysis is frequently associated with hae-
moglobinuria and acute kidney injury (AKI) [12–15]. 
When haemoglobin and haem scavengers, haptoglobin 
and haemopexin, are saturated the haemoglobin is fil-
tered through the glomerulus. It is then re-absorbed and 
catabolized in the proximal tubule. Haemoglobinuria 
results when re-absorption capacity is reached [16]. Stud-
ies implicate cell-free haemoglobin in the mechanism 
of AKI in haemolytic conditions [17, 18]. This report 
describes the first case of a patient from an unstable 
malaria transmission area presenting with delayed-onset 
haemolysis complicated by acute kidney injury following 
treatment of severe malaria with intravenous artesunate 
and follow-on oral artemether lumefantrine combination 
treatment.
Case presentation
A 45-year-old, previously well, Bangladeshi male pre-
sented to Chittagong Medical College Hospital with a 
4-day history of fever, headache, prostration, myalgias, 
nausea, and anorexia. This center is the main referral hos-
pital for the Chittagong Division in southern Bangladesh, 
which is endemic for malaria with unstable transmission. 
One day prior he was diagnosed with malaria based on a 
positive rapid diagnostic test (RDT).
There was no significant past medical history, specifi-
cally no prior malaria infections, chronic illness, jaundice, 
liver or kidney disease, transfusions, malignancy, or auto-
immune disease. There was no history of passing red or 
black urine. He was not taking any regular prescription 
or traditional medications and had no prior exposure to 
artemisinins.
On admission (day 0), his temperature was 40.3°C, 
Glasgow Coma Score (GCS) 15/15, blood pressure (BP) 
117/62  mmHg; heart rate (HR) 102 beats per minute 
(bpm) and respiratory rate 36 breaths per minute with 
98% oxygen saturation. He appeared well with mild dehy-
dration and scleral icterus, but otherwise unremark-
able examination. He was diagnosed with uncomplicated 
malaria on admission and received one dose of oral 
artemether/lumefantrine combination (AL) 80/480  mg 
(Novartis) since he had no clinical criteria for severe 
malaria, no initial blood tests and only an RDT-positive 
test.
Subsequent blood tests confirmed a diagnosis of severe 
falciparum malaria based on hyperparasitaemia (13.8% 
erythrocytes infected; 659,000 parasites/μL) and hyper-
bilirubinaemia (bilirubin 80  μmol/L). He was promptly 
switched to intravenous artesunate 120  mg, 2.4  mg/
kg body weight, (Guilin No. 2, Pharmaceuticals, China) 
and received three doses at 12-h intervals. He was also 
randomized to the normal saline arm of a randomized 
controlled trial of adjunctive l-arginine in severe malaria 
(ACTRN12612000571875). After 24  h he defervesced 
and was switched to oral AL for 3 days (total of 480 mg 
artemether and 2,880  mg lumefantrine). His recovery 
was unremarkable except for a delayed parasite clearance 
(estimated half life 8.2  h). Due to this persistent parasi-
taemia, he received a second 3-day course of AL and his 
parasites cleared at 148 h. In total he received 13 doses of 
AL (total dose of 1,040 mg of artemether and 6,240 mg of 
lumefantrine) and three doses of intravenous artesunate 
(total dose of 360  mg). He was discharged 8  days later 
with full recovery, a stable haematocrit and creatinine at 
a baseline of 86 μmol/L.
At follow-up on day 14 after admission he was asymp-
tomatic, however his white blood count revealed a sig-
nificant leukocytosis and severe normocytic anaemia 
(haemoglobin of 60 g/L; Table 1). He declined re-admis-
sion and subsequently experienced fever, rigors, head-
ache, jaundice, abdominal pain, and vomiting. He had 
not taken any antibiotics, non-steroidal anti-inflamma-
tories or proton pump inhibitors during this intercurrent 
period after treatment of the initial malaria episode.
He was re-admitted on day 20 feeling unwell with 
generalized oedema, particularly of the face and lower 
extremities. Vital signs were stable: temperature 36.5°C, 
GCS 15, BP 130/74 mmHg and HR 78 bpm. He appeared 
sick, anaemic and had periorbital oedema. Cardiac exam-
ination revealed a systolic flow murmur at the left upper 
sternal border with no radiation. There was mild abdomi-
nal tenderness on palpation and bilateral lower limb 
pitting oedema. Biochemistry revealed AKI with a cre-
atinine increased to 1,769 μmol/L, hyperkalaemia, a non-
anion gap hyperchloraemic metabolic acidosis and severe 
anaemia with 4+ haemoglobinuria (Table 1), with other 
investigations outlined below. Bladder catheterization 
did not suggest urinary retention with a residual volume 
of less than 50  mL of dark orange urine. He promptly 
received calcium gluconate and insulin for hyperkalae-
mia, empiric ceftriaxone, and was referred for haemo-
dialysis and blood transfusion. Following five rounds of 
haemodialysis and three units whole blood transfusion, 
his metabolic acidosis, hyperkalaemia, renal function, 
and anaemia improved (Figure 1).
He was discharged recovering well on day 44 with 
stable serum creatinine and haemoglobin. He was fol-
lowed up weekly thereafter, and by day 81 his kidney 
function improved further towards baseline (creatinine 
115 μmol/L), and his haemoglobin recovered (135 g/L).
Investigations
Investigations are summarized in Table  1. Samples sent 
to Thailand and Australia for specialized tests are indi-
cated by an asterisk. On day 20, reticulocytes accounted 
for 3% of erythrocytes (reticulocyte production index 
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0.4). The direct antiglobulin test (DAT; anti-IgG and anti-
C3d) and indirect antiglobulin test (IAT) were negative. 
Plasma cell-free haemoglobin* was elevated (127,000 ng/
mL; normal range <124,000  ng/mL), and haptoglobin* 
decreased (5 μg/mL; normal range: 300–2,000 μg/mL). A 
24-h urine collection revealed 525 mg of protein (normal 
range <150 mg/day). Urine microscopy showed red blood 
cells casts and dysmorphic red cells. Urine biochemis-
try*: osmolarity 283 mOsm/kg, sodium 84 mmol/L, urine 
anion gap of 8, urine osmolar gap 21, and transtubular 
potassium gradient 1.8. Anti-nuclear antibodies were 
absent and C3/C4 levels were normal. HIV and hepati-
tis C antibodies, hepatitis B surface and envelope antigen 
were negative. Blood cultures and bacterial 16S* riboso-
mal DNA amplification performed to exclude bacterae-
mia as a cause of the leukocytosis were negative. Repeat 
peripheral blood smears for malaria were negative and no 
schistocytes were found. Glucose-6-phosphate dehydro-
genase (G6PD) was qualitatively normal on day 0.
Abdominal ultrasound on day 22 showed normal kid-
ney size with increased parenchymal echogenicity and 
poor corticomedullary differentiation, with no pelvical-
yceal system dilatation.
A renal biopsy performed on day 27 revealed severe 
and recovering acute tubular injury, with interstitial 
oedema but only minimal tubulointerstitial inflammation 
(Figure  2). Tubules showed acute tubular dilatation, 
injury and regenerative features. Several red cell casts 
and amorphous casts were present. Vessels were normal. 
Glomeruli were morphologically normal with no active 
glomerulonephritis, negative immunoperoxidase stain-
ing for immunoglobulins and C3, and no immune com-
plex deposition or basement membrane abnormalities 
on electron microscopy. A myoglobin immunostain was 
negative in casts. However, a Perl’s stain for iron showed 
both diffuse tubular staining and increased deposition in 
granular deposits within the cytoplasm of damaged tubu-
lar epithelial cells.
Discussion
This report describes a case of post-artesunate delayed-
onset haemolysis complicated by acute kidney injury 
after recovery from severe falciparum malaria with 
hyperparasitaemia. Identifying the cause of haemolytic 
anaemia following malaria infection is challenging, as 
its mechanism is multifactorial and the broad differen-
tial diagnosis requires specialized testing that is often 
unavailable in resource-limited settings. The timing of 
haemolysis in this case 14  days after the first dose of 
artesunate accompanied by a >10% drop in haemoglo-
bin (from day 7 haemoglobin), haptoglobin <0.1  g/L 
and lactate dehydrogenase >390 U/L is consistent with 
Table 1 Investigations
a Specialized tests performed on samples sent to Darwin, Australia.
Parameter Day 0 Day 3 Day 14 Day 20 Day 44 Normal range
Plasma haemoglobin (ng/mL)a 177,839 – – 127,146 – <124,000
Haemoglobin (g/L) 141 136 60 49 102 140–180
Haematocrit (%) 43.6 40 18.7 16 27.1 47–54
Mean corpuscule volume (fL) 86.3 – 86.2 94.7 85.2 76–96
Plasma haptoglobin (μg/mL)a 1,160 – – 5 – 300–2,000
Platelets (×103/μL) 28 – 228 478 320 150–00
White blood cells (×103/μL) 6.23 – 19.9 9.8 10.5 4–10
Neutrophils (%) 83 – 70 60 40–70
Creatinine (μmol/L) 97 86 – 1,769 132 53–115
Potassium (μmol/L) 3.7 4.4 – 8.4 4.8 3.5–4.9
Venous pH 7.41 – – 7.2 – 7.31–7.41
Venous bicarbonate (mmol/L) 19.5 – – 8.7 – 23–28
Venous carbon dioxide (mmHg) 31.2 – – 23.5 – 41–51
Venous base excess (mmol/L) −5 – – −20 – (−2) to (+3)
Venous lactate (mmol/L) 2.36 – – 0.58 – 0.9–1.7
Anion gap (mmol/L) 13 – – 6 – 10–20
Total bilirubin (μmol/L) 80 – – – – 3–21
Indirect bilirubin (μmol/L) 26 – – – – 2–14
Lactate dehydrogenase (U/L) 592 – – 887 – 140–280
International normalization ratio – 1.3 – – – 0.8–1.2
Partial thromboplastin time (seconds) – 15 – – – <30
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Figure 1 Haemoglobin, haematocrit, creatinine, and lactate dehydrogenase profiles from both hospital admissions. The first admission for severe 
malaria with hyperparasitaemia and hyperbilirubinaemia from day 0 to day 8; second hospital admission for severe haemolytic anaemia and 
acute kidney injury from day 20 to day 44. a Haemoglobin and haematocrit profile during hospital admissions. Haematocrit was stable during 
first hospital admission. Haemoglobin dropped by 57 and 65% on days 14 and 20, respectively, and recovered by day 81. Arrows indicate timing of 
whole blood transfusions on days 20 and 21; b haemoglobin and lactate dehydrogenase (LDH) profile during hospital admissions; c haemoglobin 
and creatinine profile during hospital admissions. Acute kidney injury, with a creatinine increase by 21× on second hospital admission, classified 
as stage 3 according to AKIN criteria and ‘failure’ by RIFLE criteria. Presumed baseline creatinine from day 1 was 74 μmol/L. His creatinine returned 
close to baseline by day 81 (106 μmol/L). Asterisks indicate haemodialysis on days 20, 21, 23, 25, and 30; ‘B’ indicates renal biopsy on day 27. AKIN 
acute kidney injury network, RIFLE risk, injury, failure, loss, end-stage kidney disease.
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the case definition of PADH [5, 7, 8]. Since 2012, PADH 
is proposed to have occurred in at least 38 patients [19, 
20], however these reports do not strictly adhere to the 
optimized definition of PADH recently published in 
2014 [5, 7]. Given this limitation it is difficult to accu-
rately determine the frequency and clinical impacts 
of PADH. A recent review of the reported cases with 
an alternative PADH case definition estimates that 
among severe malaria patients treated with intravenous 
artesunate PADH occurs in 13% and blood transfusions 
are required in 9% [20]. Of these PADH cases, 31 were 
non-immune returning travellers, six were immune 
African children under 5 years, and one was an immune 
West African adult [6, 9–11, 20–26]. The case reported 
here describes PADH in a non-immune adult Bangla-
deshi patient who recovered from an episode of severe 
malaria acquired while living in an unstable malaria 
transmission region.
The mechanism of PADH is hypothesized to be due 
to pitting of ring staged parasitized red cells, where the 
spleen removes the dead parasite from the red cell akin to 
the removal of Howell–Jolly bodies [5]. These pitted cells 
are formed quickly after treatment with artesunate and 
have a shortened red cell survival [27–29]. Destruction of 
the once-infected pitted cells manifests as delayed onset 
of haemolysis. However, in this case and other reported 
cases of PADH [30] the magnitude of the drop in haemo-
globin exceeds the fall expected if only the once-infected 
pitted cells are destroyed. This suggests that additional 
artesunate-associated mechanisms of delayed haemoly-
sis involving uninfected red cells must occur. Inhibition 
of erythropoiesis has also been proposed to contribute to 
the anaemia as it has been suggested that patients receiv-
ing higher doses of artesunate are at higher risk of bone 
marrow suppression [7]. This may have contributed to 
the anaemia in the presented case as he received a total 
Figure 2 Renal biopsy. Left kidney ultrasound guided biopsy performed on day 27. Photomicrographs to show histopathological findings; a acute 
tubular necrosis with dilation, epithelial thinning, tubular cell necrosis and regeneration, interstitial oedema, and minimal inflammation (haematoxy-
lin and eosin stain ×200); b acute tubular injury with PAS staining showing loss of brush border in the dilated injured proximal tubules (Periodic acid 
Schiff ×200); c a normal glomerulus (×400 Jones methanamine silver stain), and d a Perls stain for iron showing particulate and diffuse staining in 
damaged proximal tubules (×400). Specialized PAS, methanamine, and Perls straining were performed in Bangkok, Thailand since only haematoxy-
lin and eosin stain was available in Bangladesh.
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dose of 7.2 mg/kg artesunate and 20.8 mg/kg artemether, 
and a day 20 reticulocyte production index of <2% sup-
ported an inadequate bone marrow response to his hae-
molysis. The young ring-stage activity of artesunate is 
one characteristic that confers its life-saving benefit over 
quinine. Artesunate remains first-line anti-malarial for 
the treatment of severe malaria since the benefit of sur-
vival outweighs the low probability of non-life-threaten-
ing delayed haemolysis. Recent guidelines recommend 
weekly monitoring malaria patients for indicators of hae-
molysis for 1 month following treatment with artesunate 
[30].
This case of delayed haemolysis was complicated by 
severe AKI, which has not been reported in the setting of 
PADH. The presence of excess haem pigment in tubular 
cells may be due to re-absorption from tubular red cells or 
haemoglobinuria. The role of haemoglobinuria has been 
associated with AKI in a spectrum of diseases including 
blackwater fever, babesiosis, paroxysmal nocturnal hae-
moglobinuria, massive transfusion and post-cardiopul-
monary bypass [12–15, 17, 18, 31]. While not all cases 
of haemoglobinuria result in AKI, up to 64% of patients 
with blackwater fever develop renal dysfunction [14]. In 
this case the features suggested direct tubular epithelial 
toxicity due to free haem rather than a cast nephropathy. 
The pathophysiology of haem-pigment AKI is not com-
pletely defined but vasoconstriction; direct tubular cell 
injury and tubular obstruction are thought to contribute 
[32]. There is accumulating evidence that haemoproteins 
induce oxidative renal damage by lipid peroxidation [17, 
33]. The redox cycling of the haem group initiates lipid 
peroxidation, releasing potent oxidative compounds that 
cause renal vasoconstriction [33]. This mechanism is 
demonstrated in post-operative AKI after post-cardio-
pulmonary bypass where high cell-free haemoglobin and 
oxidative stress were associated with kidney injury [17, 
18]. Cell-free haemoglobin is also likely to cause vasocon-
striction through its quenching of endothelial nitric oxide 
(NO) in severe falciparum malaria, where it has been 
associated with impairment in NO-dependent endothe-
lial function [34]. The renal pathology in this case is con-
sistent with haem-pigment induced AKI with clinical 
evidence of non-anion gap hyperchloraemic metabolic 
acidosis with distal tubule dysfunction likely secondary 
to hypovolaemia and vasoconstriction.
The differential diagnosis for haemolysis in this case is 
broad and the possible contribution of an intercurrent 
bacterial infection between admissions was considered 
given his leukocytosis on day 14. Infections may cause 
haemolysis by precipitating oxidative stress in patients 
with underlying red blood cell (RBC) disorders, inducing 
haemolytic pathologic responses, or from the antimicro-
bial therapy itself [35]. Limited diagnostics suggested no 
underlying RBC abnormality: normal qualitative G6PD, 
mean corpuscular volume (MCV) and peripheral smear. 
Negative DAT and IAT argued against an immune-medi-
ated haemolytic anaemia. Infections characterized by 
haemolysis include: malaria, babesiosis, Carrion’s disease, 
and typhoid. The peripheral smear on second admission 
revealed no intra-erythrocytic organisms. Negative blood 
cultures and bacterial 16S ribosomal DNA amplifica-
tion were not conclusive but argued against infection as 
a cause of the haemolysis. Furthermore, the leukocytosis 
observed on day 14 had resolved by day 20 in the absence 
of antibiotic treatment.
The differential diagnosis for the etiology of AKI 
included (1) pre-renal, and (2) intrinsic renal causes 
including: acute tubular injury (ATI) due to ischaemia or 
direct toxin-mediated injury by cell-free haemoglobin, 
acute interstitial nephritis (AIN) secondary to β-lactams, 
microangiopathy, or post-infectious glomerulonephri-
tis (PIGN). The urinary osmolarity <350  mOsm/kg and 
fractional excretion of sodium >1% did not suggest a 
pre-renal cause. The absence of systemic eosinophils 
and eosinophil-rich tubulo-interstitial inflammation on 
renal biopsy argued against a diagnosis of AIN, although 
recovering AIN can be pauci-inflammatory. The normal 
platelets, lack of schistocytes, negative blood cultures and 
16S rRNA amplification, and normal renal vessels and 
glomeruli on biopsy were not consistent with haemolytic 
uraemia syndrome/thrombotic thrombocytopenic pur-
pura or PIGN.
Treatment for established AKI is limited to renal 
replacement therapy. Research towards prevention and 
alternative treatments is vital since dialysis is frequently 
unavailable. Currently, there is no targeted treatment 
for cell-free haemoglobin-induced AKI, however results 
from experimental models and case series are encourag-
ing. Recent studies have shown that paracetamol inhib-
its haemoprotein-induced lipid peroxidation, resulting 
in decreased oxidative kidney injury and improved renal 
function [36, 37]. Administration of haptoglobin infu-
sions is shown to attenuate cell-free haemoglobin-medi-
ated AKI in paroxysmal nocturnal haemoglobinuria and 
an experimental model of stored blood transfusion [38, 
39].
Conclusions
Malaria treatment guidelines should consider recom-
mending that renal function be checked if a drop in 
haemoglobin is detected during monitoring of severe 
malaria patients after treatment with artesunate. This 
may be logistically difficult in limited-resource coun-
tries but where it can be done, monitoring the creatinine 
should be a part of severe malaria management to detect 
and avoid renal complications.
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Learning points
Delayed onset haemolytic anaemia following parasite 
clearance in severe malaria infection has a broad dif-
ferential diagnosis to consider.
Delayed onset haemolysis following severe malaria 
may occur following artesunate treatment, and be 
complicated by AKI.
Severe malaria patients treated with artesunate should 
be monitored weekly for decline of haemoglobin and 
renal function.
There are limited treatment options to treat haemo-
protein-mediated AKI.
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